Patients taking Ozempic and Wegovy for weight loss are reporting something unexpected: they've lost interest in alcohol. Some have quit smoking without trying. Researchers are now racing to understand why—and whether GLP-1 drugs could revolutionize addiction treatment.
The Accidental Discovery
It started with patient reports. People on semaglutide (Ozempic/Wegovy) weren't just eating less—they were drinking less. Smoking less. Some reported reduced interest in gambling, shopping, even nail-biting.
A 2023 retrospective study of 80,000+ patients found those on semaglutide had 50-56% lower rates of alcohol use disorder compared to those on other obesity medications.
Source: Wang et al., Nature Medicine, 2023How GLP-1 Drugs Affect the Brain
GLP-1 receptors aren't just in the gut—they're throughout the brain, including reward centers:
- Reduces dopamine release in response to rewards
- Dampens the 'wanting' signal for addictive substances
- May reduce impulsivity via prefrontal cortex effects
- Decreases alcohol-seeking behavior in animal studies
Unlike naltrexone, which blocks opioid receptors, GLP-1 drugs appear to modulate the entire reward system more broadly.
Current Evidence
Alcohol
A Phase 2 trial showed semaglutide reduced heavy drinking days by 70% in people with alcohol use disorder—far exceeding current FDA-approved treatments.
Source: Klausen et al., eClinicalMedicine, 2022Nicotine
Observational studies show reduced cigarette consumption. Clinical trials for smoking cessation are now underway.
Opioids and Stimulants
Animal studies are promising. Human trials are in early stages at multiple academic centers.
Ongoing Clinical Trials
- Penn Medicine: Semaglutide for alcohol use disorder (Phase 2)
- NIDA: GLP-1 agonists for cocaine and opioid use disorders
- University of North Carolina: Tirzepatide for binge eating and alcohol
- Multiple trials for smoking cessation
Important Caveats
- Side effects: nausea, vomiting, pancreatitis risk
- Unknown optimal dosing for addiction
- May not work for everyone
- Expensive without insurance ($1,000+/month)
- Long-term effects unknown
- Stopping may lead to relapse
What This Could Mean
If trials succeed, GLP-1 drugs could become the first truly effective pharmaceutical treatment for alcohol use disorder since... well, ever. Current options (naltrexone, acamprosate, disulfiram) have modest effects. A 50-70% reduction in heavy drinking would be transformative.
The Bottom Line
The GLP-1 addiction connection is one of the most exciting developments in psychiatry in years. But we're still in early days. If you're struggling with addiction, proven treatments exist now—therapy, support groups, existing medications. Don't wait for the perfect pill when help is available today.